Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer.

ABSTRACT:

Background

Platinum based agents-cisplatin and carboplatin in combination with taxanes are used for the treatment of ovarian cancer (OC) patients. However, the majority of OC patients develop recurrent, platinum resistant disease that is uniformly fatal. Platinum treatment enriches for chemoresistant aldehyde dehydrogenase (ALDH) + ovarian cancer stem cells (OCSCs), which contribute to tumor recurrence and disease relapse. Acquired platinum resistance also includes metabolic reprograming and switching to oxidative phosphorylation (OXPHOS). Chemosensitive cells rely on glycolysis while chemoresistant cells have the ability to switch between glycolysis and OXPHOS, depending on which pathway drives a selective advantage for growth and chemoresistance. High expression of genes involved

SUBMITTER: Sriramkumar S 

PROVIDER: S-EPMC9153190 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature